Bristol Myers Squibb ZENBEXUS cuts progression risk 51%
Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 EXCALIBER-RRMM results showing median progression-free survival of 42 months with ZENBEXUS-based treatment versus 20 months with the comparator regimen.











